Report: Sales of energy shots set to double
NEW YORK Sales of energy shots are expected to nearly double this year, according to a New Your Times report published Saturday, to some $700 million citing Consumer Edge Research projections, which do not include projected sales from Walmart.
The market is dominated by Living Essentials, which fields the premiere energy shot — 5-Hour Energy. According to the Times report, Living Essential’s sales account for approximately 80% of the market.
However, the market for energy shots is heating up — Red Bull brought its venerable energy-drink brand name into the mix with the introduction of a 2-oz. shot last month, and Dr Pepper Snapple recently began test-marketing a 3 oz. version of its Venom energy drink, called Venom Bite. Coca-Cola last year introduced a shot based on its NOS energy drink.
Perrigo receives FDA approval for smoking-cessation lozenges
ALLEGAN, Mich. Perrigo on Monday announced that it has received Food and Drug Administration approval for its over-the-counter coated nicotine polacrilex lozenge, 2 mg and 4 mg, in cherry and cinnamon flavors.
The new products will be marketed under store brand labels and are comparable with GlaxoSmithKline’s smoking cessation product Commit lozenge.
“These two approvals expand our exclusive position in the store brand nicotine lozenge category,” stated Perrigo chairman and CEO Joseph Papa. “The expanded range of smoking cessation products also includes coated mint and Fruit Chill-flavored gum, uncoated gum and lozenges.”
The smoking cessation category is selling at an annual rate estimated at approximately $1 billion at all retail outlets, Perrigo reported.
Study finds that use of Premarin Vaginal Cream relieves vaginal atrophy symptoms
COLLEGEVILLE, Pa. A study published in the July/August issue of Menopause: The Journal of the North American Menopause Society supported daily and twice-weekly use of Premarin (conjugated estrogens) Vaginal Cream to relieve symptoms of moderate-to-severe vulvar and vaginal atrophy, including painful intercourse, Wyeth Pharmaceuticals announced Monday.
In this study, dyspareunia (painful intercourse) was the most bothersome symptom at baseline (57%) followed by vaginal dryness, itching and burning. Unlike hot flashes or night sweats, signs and symptoms of vaginal atrophy have been shown to increase over time in postmenopausal women.
“Based on market research data, we understand that many postmenopausal women are not discussing their symptoms with their health care professionals,” stated Gloria Bachmann, lead study author and director of the Women’s Health Institute at the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School. “We are encouraged by this 52-week data that showed twice-weekly use of Premarin Vaginal Cream was sufficient to provide relief from painful intercourse due to menopause. The study also supported daily use of Premarin Vaginal Cream 0.5 g to treat postmenopausal vaginal dryness. This information should aid postmenopausal women and their health care professionals in discussing whether and how they may treat vaginal atrophy.”